METHOD FOR DETERMINING LOSARTAN, ITS MAIN METABOLITE LOSARTAN CARBOXYLIC ACID AND GLIBENCLAMIDE IN HUMAN BLOOD SERUM AND URINE Russian patent published in 2021 - IPC A61K31/4178 A61K31/64 A61P9/12 A61P3/10 G01N30/72 G01N33/15 G01N30/06 

FIELD: medicine; pharmacology.

SUBSTANCE: invention relates to medicine, namely to pharmacology, it can be used for sample preparation with simultaneous determination of losartan, its metabolite losartan carboxylic acid (E-3174) and glibenclamide by high-performance liquid chromatography with mass spectrometric detection (HPLC-MS/MS) in human blood serum and/or urine. In the pre-prepared calibration and analysis samples, which are human blood serum and/or urine, an effective amount of the internal standard, which is a promethazine solution at a concentration of 100 ng/ml, is added. Next, an effective amount of the protein precipitator, which is undiluted acetonitrile, is added, and then mixed to a homogeneous state, followed by centrifugation at a centrifugal acceleration of 15294 g until it is separated into solid and liquid phases, with further selection of the effective amount of the supernatant. Chromatographic separation of the sample components is performed in the gradient elution mode, followed by the detection of a signal with positive ionization for losartan, its metabolite E-3174, glibenclamide, and the internal standard promethazine. This method is used to determine losartan, its metabolite E-3174 and glibenclamide in human blood serum and/or urine.

EFFECT: method makes it possible to perform sample preparation for the determination of losartan, its metabolite E-3174 and glibenclamide, which allows determining the analyzed substances, with their joint or separate presence in human blood serum and/or urine, by using a unified sample preparation scheme for all analyzed substances using undiluted acetonitrile, centrifuging the sample once, using promethazine, as a single internal standard for all analyzed substances.

9 cl, 18 dwg, 6 tbl, 10 ex